Europa are delighted to link with I3E and look forward to early September Serenity appraisal spud. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhrm Regulatory News (PHRM)

  • There is currently no data for PHRM

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Final Results for the Year Ended 31 December 2013

Fri, 27th Jun 2014 07:00

RNS Number : 6891K
Phorm Corporation Limited
27 June 2014
 

27 June 2014

Phorm Corporation Limited

("Phorm" or the "Company")

Final Results for the Year Ended 31 December 2013

 

Phorm (AIM: PHRM), a leading internet personalisation technology company, announces its audited final results for the year ended 31 December 2013. Copies of the Company's full Annual Report and Financial Statements are being posted to shareholders today and will also be made available to download from the Company's website at www.phorm.com.

 

Highlights:

· Total revenue of $279,750 (2012: $63,291)

· Operating loss of $35.1 million (excluding share based payment expense) (2012: $31.6 million)

· Launched with 8 further ISPs globally, in addition to TTNET in Turkey 

· Significant increase in global user numbers to over 30 million daily unique users

· Advertising performance remains strong

· Pricing has increased by between 35% and 94%, depending on the product

· Memorandum of Understanding signed with China Telecom, naming Phorm as its preferred strategic partner for Online Advertising and 'Big Data' initiatives

· Equity placings of $39.8 million (net $38.4 million) successfully completed

 

Turkey

· Delay in commercialisation, primarily due to the re-design of the invitation process following the release of the revised BTK regulatory guidelines in December 2012

· Significant recent increase in user numbers, from approximately 1 million to more than 5 million

· Advertising platform is now able to use both cookie-based and ISP data

· Inventory available for opted-in users has increased to over 2 billion advertising requests per month

· Commercial scale has now been achieved

· Advertising revenue is growing rapidly which is expected to continue throughout 2014

 

Rest of World

· Memorandum of Understanding signed with China Telecom, valid for three years

· Phorm is now China Telecom's preferred strategic partner for 'Big Data' and Online Advertising

· Agreement signed with national partner to accelerate the roll-out of Phorm's technology in China

· Integration with major advertising network in China providing access to over 5 billion advertising requests per month for opted-in users

· Commercial launch with Chinese ISPs, initial paid-for test campaigns currently in progress

· Operations have been scaled back in Brazil and Romania in order to focus on markets with higher near term growth potential

Finances

· In 2013, the Company completed equity placings to raise, in aggregate, $39.8 million (net $38.4 million), which enabled the business to launch its commercial operations in Turkey and to continue to develop opportunities in China and elsewhere

· In March 2014, the Company completed a further equity placing to raise $16.7 million (gross)

For further information please contact:

Phorm Corporation Limited

Andy Croxson (analysts and investors) +44 203 397 6001

 

UK Investors

Mirabaud Securities LLP (Broker) +44 20 7321 2508

Jason Woollard

Peter Krens

Strand Hanson Limited (Nominated Adviser) +44 20 7409 3494

James Harris

Matthew Chandler

James Dance

 

US Investors

Lippert/Heilshorn and Associates (Investor Relations) +1 212 838 3777

John Heilshorn

 

About Phorm

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience.

Phorm's industry leading technology enables its Internet Service Provider ("ISP") partners to offer a new type of online advertising platform and a free consumer internet content feature, ensuring more relevant advertisements and personalised content for opted-in users.

Phorm's advertising platform revolutionises current standards of online privacy, fully protecting the identity of consumers. Phorm's solution is completely opt-in. Only those users consenting to the service are profiled and only ever on an anonymous basis.

Phorm's partners include leading ISPs, Publishers, Advertising Networks and Advertisers.

Phorm, under a predecessor holding company, was admitted to the AIM market of the London Stock Exchange in 2004.

 

For more information, please visit: www.phorm.com

Chairman and chief executive officer's statement

I am pleased to report upon the further progress made by the Group during the financial year ended 31 December 2013 and on our subsequent on-going activities to the date of this statement.

Operational performance

Historically, the major challenge facing Phorm has been to build a large user base. We learned, during the course of last year, that our technology worked. Across several dozen case studies in Turkey, we were able to deliver highly effective advertising in the text and display space. However, even though it was large enough to prove the business model and demonstrate the power of the technology, the scale at which we were able to operate remained too small deliver significant revenues. In recent months the Company has made dramatic progress in this regard. At the start of 2013, the Company had just one commercially operational ISP partner, it now has nine globally. The number of daily unique users in the same period has grown from less than 2 million to over 30 million as the Company previously announced on 27 March 2014. The very significant increase in users gives Phorm great confidence that this scale will translate into large revenues as a result of advertiser demand for the product.

The cornerstone upon which scale in the business is being built is advertising performance. The current text advertising market is dominated by search engines, which have demonstrated a hitherto unique ability to target advertising at the keyword level based upon search terms entered by individual users. Phorm's system, the Open Internet Exchange, is able to discern audience-buying intent by anonymously understanding repeat keyword activity across multiple pages. Of particular note is that despite Phorm's system being able to address a specific audience without reference to search, the propensity of users who click on our advertisements to then go on to purchase or take some desired action has, in a large number of cases, significantly exceeded their propensity to do so on the same advertisement shown on a search engine. This has created a situation where demand for our product exceeds supply by a considerable margin. Compared to last year, our pricing has increased between 35% and 94% depending on the product and a large share of our advertisers have re-booked campaigns for the past six months.

In Turkey, the ability of the business to generate large-scale revenue has been held back by the relatively slow growth - until recently - in the number of users. Low user numbers have meant that, in many cases, Phorm has been unable to accept the full campaign budgets available from advertisers who require specific budgets and, hence, volumes to be consumed within a given time-frame. The more tightly advertisers target specific behaviours, the smaller the available volume of users who exhibit those behaviours. With just over 1 million users, therefore, Phorm lacked the user numbers and, hence, campaign volumes necessary to consume large budgets. However, in the last month the number of daily unique users has grown from just over 1 million to more than 5 million, as a result of supplementing ISP data, as appropriate, with traditional cookie-based data. We are now working with our advertising partners to increase campaign size and the prospects for the business in Turkey look very good.

Outside Turkey, the growth in users has been even more remarkable. Phorm is now commercially live with a further eight ISP partners and well over 25 million users. Although the non-Turkish users are now live and opted-in, the Company is still in the ramp up process of building the publisher partnerships and commercial advertising pipeline to address this audience. However, early results in non-Turkish markets suggest that advertising performance will meet or exceed that achieved in Turkey. In China, we expect to achieve in excess of 50 million users opted in this year, the Company previously announced on 27 March 2014 that it had reached 30 million daily unique users globally.

There are four main drivers of the business: users, publishers, advertisers and advertisement performance.

1. Users

A user is defined as a unique ID which can be profiled for the purpose of delivering targeted content and advertising. Over the last six months user numbers have increased by a factor of over 15 and the strength of growth outside Turkey ensures that the ultimate success of the Company has been substantially de-risked. Phorm expects strong user growth to continue in 2014 as the Company progressively signs up more ISPs in multiple markets.

2. Publishers

Over the past twelve months the Company significantly increased the amount of inventory to which it had access. Integrating with ad exchanges as well as advertising networks and direct publishers provided access to over 900 million of advertising requests per day at peak. This demonstrates the potential for large-scale revenues as user numbers grow. The Company is continuing to integrate with a wide variety of players in the eco-system and this has provided a further substantial increase in the amount of inventory available to the platform.

The Company, globally, now has access to over 18 billion advertising requests per month across thousands of websites.

3. Advertisers

In 2013 the Company delivered both targeted display and targeted text advertising. The response that the Company has received from advertisers for both products has been excellent. The Company is now working with all of the top five global advertising agencies, through their local subsidiaries.

The key focus for the Company now is to deliver substantial volume. While the growth of the global advertiser pipeline is still at an early stage it is expected that substantial volume can now be achieved as the result of the recent growth in users and inventory in 2014. Bolstering the global sales effort through recruitment, training and broad presentation to market players is now the Company's main focus.

4. Performance

Phorm's advertising platform, the OIX, provides an unprecedented level of targeting, on an anonymous basis. This has enabled advertisers to address precisely the audiences that they are trying to reach. The result has been very strong performance. The effectiveness of the advertising is measured in post click and post view conversions.

In many cases, the Company has been able to demonstrate that it can deliver superior conversion performance in comparison to the market leader across multiple advertising sectors. This is particularly exciting as the optimisation of the system is still at a relatively early stage. The conversion performance will under-pin future growth as this is a key metric used by the advertisers.

Strategic partnerships

We were also pleased to announce a memorandum of understanding with China Telecom. This MOU, which names us as a preferred strategic partner for Online Advertising and Big Data initiatives, is a reflection of the progress which we are making on the ground in furthering ISP partnerships across numerous additional provinces

The Company is continuing with its strategy of focusing on those global markets that can deliver results quickly and the success of this strategy can be seen by the growth in the key value drivers over recent months.

Legal Action

The Company has, for several years now, been subject to a very active campaign by a known group of individuals whose primary goal has been to harm the business and its employees through the dissemination of false information to partners and investors. These individuals have also adopted tactics designed to harass and intimidate the Company and its employees. Accordingly, we have recently obtained an interim injunction against one of these individuals, preventing him from continuing such activity against me and other employees of Phorm. The Company intends to vigorously defend its reputation and employees against such actions in the future.

Funding and going concern

In 2013, the Company completed share placings of £25.2m, which enabled the business to launch its commercial operations in Turkey and to continue to develop opportunities in China and elsewhere. However, the re-design of the invitation process led to a delay in the commercialisation of the Turkish opportunity and, as a result, further fund raising was required.

In March 2014, the Company announced that it had successfully completed a placing of £10.0m in shares.

During the course of this year, we have begun to introduce ourselves to US and Chinese capital markets. Response to our progress has been strong as demonstrated by the participation of several US investors in the £10 million raised in March 2014. We expect this exposure to the US investor base to increase significantly during the course of this year.

As a result of the extended delays involved in reaching the current operational stage, the Company has seen a substantial decrease in its stock price. It has nevertheless retained the support of key shareholders who currently account for more than 60% of the Company's shareholding.

The delays described above have meant that revenues have not grown as rapidly as expected. The Company is very encouraged by the progress made but, nevertheless, further funds will be required in the near term. The business plan approved by the Directors forecasts the need for this further funding and access to sufficient working capital to allow the operating businesses to reach full commercial scale. This is the principal risk to the business at the current time.

At the date of approval of these financial statements, the Group has yet to secure the additional funding requirements set out in the business plan and is, therefore, not fully-funded at the current time. However, given the success of the recent fund raising activities and the operational progress that has been achieved, the Directors are confident that this further funding will be achieved as required. As at 31 May 2014, the Group held cash and cash equivalents of $8.8m.

In preparing these financial statements, the Directors have assumed that sufficient further funding will be made available to the Group to enable it to execute its business plan and realise the forecast inflows from operations in Turkey and elsewhere.

In common with similar businesses at this stage of their development, and in light of the Group's dependence on further financing being made available to it from its shareholders or other providers of finance, the Directors consider the combination of these circumstances represent a material uncertainty that may cast significant doubt upon the Group's ability to continue as a going concern and, therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business.

Nevertheless, after making enquiries, and considering the uncertainties described above, the directors have a reasonable expectation that the Group will have access to adequate resources to continue in operational existence for the foreseeable future. For these reasons, they continue to adopt the going concern basis in preparing the financial statements.

Further information in respect of the directors' assessment of going concern, including the material uncertainties identified, is set out in Note 2 to the financial statements.

Financial report

Results for the year

Revenue generation in Turkey took significantly longer than originally anticipated and was interrupted as a result of the adjustments made to the invitation process in line with the new BTK (Bilgi İletişim ve Teknolojileri Kurumu, the telecommunications authority in Turkey) guidelines. However, following the regulatory review, revenue billing restarted in June 2013. While the current revenues, at this stage, remain small, key lead indicators such as the number of pages enabled for advertising, as well as the number and value of campaigns show strong positive trends. In addition, the recent significant growth in user numbers has given the Company considerable cause for optimism and it is very pleased with the opt-in rate that it has for its invitations.

Total revenue of $279,750 was generated for the year ended 31 December 2013 (2012: $63,291). The Group expects revenue growth to be driven by a combination of four key factors: users, publisher inventory, advertising campaigns and targeting performance.

Operating losses for the year (before non-cash share-based payment charges) were $35.1 million (2012: $31.6 million). The non-cash share-based payment charges for the year were $10.7 million (2012: $26.1 million).

For the six months ended 30 June 2013, the Company reported an operating loss (before non-cash share-based payment charges) of $16.9 million; this compares to $18.2 million in the second half of the year.

Losses after taxation were $46.6 million (2012: $58.1 million). Loss per share was $0.16 (2012: $0.74).

The Group used $33.1 million (2012: $30.6 million) in funding its operating activities.

Financial position

The Company's balance sheet at 31 December 2013 showed net assets of $8.4 million (2012: net assets of $6.4 million) with cash and cash equivalents of $9.7 million (2012: $5.9 million). The year on year movement of $2.0 million is attributable to the loss for the year of $46.6 million, foreign exchange losses on translation of overseas subsidiaries of $0.3 million, offset by new share subscriptions of $38.2 million and a share-based payment of $10.7 million.

Funding

In March 2013, the Company completed the placing of £3m ($4.6m) of Loan Notes with an initial annualised coupon of 20% payable upon redemption. The funding was to take place in two tranches with £1.5m ($2.3m) being made immediately available to the Company as bridge financing.

In April 2013, the Company completed a placing of £5.2m ($8.0m) in shares and the issuance of a further £2.0m ($3.2m) in convertible secured loan notes. The Company further announced in May 2013 that it had redeemed the £1.5m ($2.3m) of convertible loan notes issued in March 2013, cancelling all further obligations.

In July 2013, the Company raised £10.0m ($15.6m) and subsequently in November 2013 raised a further £10.0m ($16.2m) through two share placings.

In March 2014, the Company announced that it had successfully completed a placing of £10.0m ($16.7m) in shares.

The proceeds of the fund raising activities were used for business expansion, capital expenditures, marketing and general working capital for the business.

 

Kent Ertugrul

 

Chairman and Chief Executive Officer

26 June 2014

 

 

Phorm Corporation Limited

 

 

Consolidated statement of profit or loss

Year ended 31 December 2013

 

 

Year ended 31 December 2013

Year ended 31 December 2012

Note

Before share based payment expense

Share based payment expense

After share based payment expense

Before share based payment expense

Share based payment expense

After share based payment expense

$

$

$

$

$

$

Continuing operations

Revenue

3

279,750

-

279,750

63,291

-

63,291

Cost of sales

(4,066,477)

-

(4,066,477)

(561,493)

-

(561,493)

 

 

 

 

 

 

Gross loss

(3,786,727)

-

(3,786,727)

(498,202)

-

(498,202)

 

 

 

 

 

 

Other operating expenses - research and development

(6,934,168)

(1,481,076)

(8,415,244)

(6,547,655)

(2,682,554)

(9,230,209)

Administrative expenses

(24,427,137)

(9,232,345)

(33,659,482)

(24,536,799)

(23,415,318)

(47,952,117)

 

 

 

 

 

 

Operating loss

(35,148,032)

(10,713,421)

(45,861,453)

(31,582,656)

(26,097,872)

(57,680,528)

Investment income

8

5,795

11,629

Financing expense

9

(748,008)

(406,177)

 

 

Loss before tax

(46,603,666)

(58,075,076)

Income tax

10

-

-

 

 

Loss for the year

5

(46,603,666)

(58,075,076)

 

 

Attributable to equity holders of the Company

(46,603,666)

(58,075,076)

 

 

Basic and diluted loss per share ($)

11

(0.16)

(0.74)

 

 

 

Consolidated statement of profit or loss and other comprehensive income

Year ended 31 December 2013

 

 

 

Year ended

31 December

2013$

Year ended

31 December

2012$

 

 

 

 

Loss for the year

 

(46,603,666)

(58,075,076)

 

 

 

 

Other comprehensive income

 

 

 

Items that may be reclassified subsequently to profit or loss

 

 

 

Exchange (loss)/gain on translation of foreign operations, net of tax

 

(317,902)

634,641

 

 

 

 

Total comprehensive loss for the year

 

(46,921,568)

(57,440,435)

 

 

 

 

 

 

 

 

Attributable to equity holders of the Company

 

(46,921,568)

(57,440,435)

 

 

 

 

 

Statements of financial position

31 December 2013

 

 

 

Group

Company

Note

2013$

2012$

2013$

2012$

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

 

Investment in subsidiary

13

-

-

16,963,152

70,591,856

 

Plant and equipment

12

1,211,291

763,514

-

-

 

 

 

 

 

 

 

 

Total non-current assets

 

1,211,291

763,514

16,963,152

70,591,856

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Amounts due from subsidiary undertakings

14

-

-

 

36,925,520

-

 

Trade and other receivables

15

6,181,141

2,383,090

3,260,657

482,781

 

Cash and cash equivalents

16

9,662,828

5,877,075

413,393

-

 

 

 

 

 

 

 

 

Total current assets

 

15,843,969

8,260,165

40,599,570

482,781

 

 

 

 

 

 

 

 

Total assets

 

17,055,260

9,023,679

57,562,722

71,074,637

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Trade payables

20

(2,916,160)

(632,405)

(1,193,223)

-

 

Other payables

21

(2,104,455)

(2,021,716)

(259,035)

(518,073)

 

Provisions

22

(164,864)

-

(164,864)

-

 

Amounts due to subsidiary undertakings

27

-

-

(382,245)

-

 

 

 

 

 

 

 

 

Total current liabilities

 

(5,185,479)

(2,654,121)

(1,999,367)

(518,073)

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

Convertible loan notes

23

(3,425,673)

-

(3,425,673)

-

 

 

 

 

 

 

 

 

Total liabilities

 

(8,611,152)

(2,654,121)

(5,425,040)

(518,073)

 

 

 

 

 

 

 

 

Net assets

 

8,444,108

6,369,558

52,137,682

70,556,564

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

Share capital

17

277,744,986

239,507,089

195,140,258

156,902,361

 

Treasury shares

18

-

-

-

-

 

Warrants

17

869,430

659,766

869,430

659,766

 

Translation reserve

 

(13,507,218)

(13,189,316)

4,621,646

1,536,343

 

Accumulated deficit

 

(256, 663,090)

(220,607,981)

(148,493,652)

(88,541,906)

 

 

 

 

 

 

 

 

Total shareholders' equity

 

8,444,108

6,369,558

52,137,682

70,556,564

 

 

 

 

 

 

 

 

 

 

Statements of changes in equity

Year ended 31 December 2013

 

Group

Share capital$

Warrants$

Treasuryshares$

Translation reserve$

Accumulated deficit$

Total$

 

 

 

 

 

 

 

At 1 January 2013

239,507,089

659,766

-

(13,189,316)

(220,607,981)

6,369,558

 

Total comprehensive

loss for the year

-

-

-

(317,902)

(46,603,666)

(46,921,568)

 

Share-based payment charge (Note 19)

-

-

-

-

10,713,421

10,713,421

 

Issue of new stock

38,237,897

122,351

-

-

-

38,360,248

 

Charge for warrants

-

87,313

-

-

-

87,313

 

Provision for

unsettled equity

(Note 22)

-

 

-

-

-

(164,864)

(164,864)

 

 

 

 

 

 

 

 

 

At 31 December 2013

277,744,986

869,430

-

(13,507,218)

(256,663,090)

8,444,108

 

 

 

 

 

 

 

 

 

 

Group

Share capital$

Warrants$

Treasuryshares$

Translation reserve$

Accumulated deficit$

Total$

 

 

 

 

 

 

 

 

At 1 January 2012

220,834,668

180,286

(341,837)

(13,823,957)

(188,630,777)

18,218,383

Total comprehensive

loss for the year

-

-

-

634,641

(58,075,076)

(57,440,435)

Share-based payment

charge (Note 19)

-

-

-

-

26,097,872

26,097,872

Issue of new stock

19,334,067

373,613

-

-

-

19,707,680

Cancellation of stock

-

(128,301)

 

-

-

(128,301)

Effects of redomicile (Note 1)

(661,646)

 

234,168

341,837

-

-

(85,641)

 

 

 

 

 

 

 

At 31 December 2012

239,507,089

659,766

-

(13,189,316)

(220,607,981)

6,369,558

 

 

 

 

 

 

 

Company

Share capital

$

 

Warrants

$

Translation reserve

$

Accumulated deficit

$

Total

equity

$

 

 

 

 

 

 

 

 

At 1 January 2013

156,902,361

659,766

1,536,343

(88,541,906)

70,556,564

 

Loss for the year

-

-

-

(59,786,882)

(59,786,882)

 

Other comprehensive income

for the year

-

-

3,085,303

-

3,085,303

 

Issue of new stock

38,237,897

122,351

-

-

38,360,248

 

Charge for warrants

-

87,313

-

-

87,313

 

Provision for unsettled equity

(Note 22)

-

-

-

(164,864)

(164,864)

 

 

 

 

 

 

 

 

Balance at 31 December 2013

195,140,258

869,430

4,621,646

(148,493,652)

52,137,682

 

 

 

 

 

 

 

 

 

Company

Share capital

$

 

Warrants

$

Translation reserve

$

Accumulated deficit

$

Total

equity

$

 

 

 

 

 

 

At date of incorporation - 7 August 2012

-

-

-

-

-

Loss for the period

-

-

 

(88,541,906)

(88,541,906)

Other comprehensive income for the period

-

-

1,536,343

 

1,536,343

 

 

 

 

 

 

Total comprehensive loss for the period

-

-

1,536,343

(88,541,906)

(87,005,563)

Issue of new stock

156,902,361

-

-

-

156,902,361

Issue of Warrants

-

659,766

-

-

659,766

 

 

 

 

 

Balance at 31 December 2012

156,902,361

659,766

1,536,343

(88,541,906)

70,556,564

 

 

 

 

 

 

 

Statements of cash flows

Year ended 31 December 2013

 

 

Group

Company

 

 

Year ended

31 December

2013$

Year ended

31 December

2012$

Year ended31 December2013

$

Period from 7 August 2012 (incorporation date)

31 December

2012

$

 

 

 

 

 

 

 

Operating loss

(45,861,453)

(57,680,528)

(59,086,764)

(88,541,906)

 

Depreciation charges

1,157,272

668,625

-

-

 

Loss/(gain) on disposal of plant and equipment

2,453

(93,487)

-

-

 

Allowance for intercompany receivables

-

-

9,619,249

8,697,200

 

Reversal of allowance for intercompany receivables

-

-

(8,697,200)

-

 

Impairment of investment in subsidiary

-

-

55,092,715

79,314,342

 

Impairment of plant and equipment

-

50,822

-

-

 

Share-based payment expense

10,713,421

26,097,872

-

-

 

Increase in trade and other receivables

(1,483,015)

(616,014)

(462,840)

(159,774)

 

Increase in trade and other payables

2,360,125

814,084

934,185

481,775

 

Increase in intercompany payable

-

-

382,216

208,363

 

 

 

 

 

 

 

Net cash used in operating activities

(33,111,197)

(30,758,626)

(2,218,439)

-

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

Interest received

5,795

11,629

-

-

 

Repayment on settlement of warrants

-

(160,860)

-

-

 

Proceeds on disposal of plant and equipment

-

142,882

-

-

 

Purchase of plant and equipment

(1,598,054)

(456,841)

-

-

 

 

 

 

 

 

 

Net cash used in investing activities

(1,592,259)

(463,190)

-

-

 

 

 

 

 

 

 

Financing activities

 

 

 

 

 

Finance lease interest paid

-

-

-

-

 

Repayment of obligations under finance leases

-

-

-

-

 

Proceeds from issue of ordinary shares

35,878,102

20,415,489

35,878,102

8,913,431

 

Increase in intercompany loan receivable

-

-

(38,342,707)

(8,913,431)

 

Proceeds from issue of secured convertible loan notes

5,263,605

-

5,263,605

-

 

Secured convertible loan note interest paid

-

-

-

-

 

Repayment of secured convertible loan note

(2,799,000)

-

(2,799,000)

-

 

 

 

 

 

 

 

Net cash generated from financing activities

38,342,707

20,415,489

-

-

 

 

 

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

3,639,251

(10,806,327)

 

(2,218,439)

-

 

Cash and cash equivalents brought forward

5,877,075

16,149,780

-

-

 

 

 

 

 

 

 

Effect of foreign exchange changes

146,502

533,622

2,631,832

-

 

 

 

 

 

 

 

Cash and cash equivalents carried forward

9,662,828

5,877,075

413,393

-

 

 

 

 

 

 

 

Notes to the financial statements

Year ended 31 December 2013

 

Basis of preparation

The financial statements have been prepared in accordance with the historical cost basis except as disclosed in the accounting policies below, and are drawn up in accordance with the provisions of the International Financial Reporting Standards ("IFRS"), International Accounting Standards ("IAS") and Interpretations issued by the International Accounting Standards Board ("Interpretations"), as adopted by the EU.

Adoption of new standards and interpretations

On 1 January 2013, the Group adopted all the new and revised IFRS, IAS, Interpretations, as adopted by the EU that are relevant to its operations and effective from that date. The adoption of these new IFRS, IAS and Interpretations, as adopted by the EU does not result in changes in the Group's accounting policies and has no material effect on the amounts reported for the current and prior years, except as mentioned below.

At the date of authorisation of these financial statements, the following new standard and interpretation has been applied in these financial statements

IFRS 13 Fair Value Measurement

The group has applied IFRS 13 for the first time in the current year. IFRS 13 establishes a single source of

guidance for fair value measurements and disclosures about fair value measurements. The scope of IFRS 13 is broad; the fair value measurements requirements of IFRS 13 apply to both financial instrument items and non-financial instrument items for which other IFRSs require or permit fair value measurements and disclosures about fair value measurements, except for share-based payment transactions that are within the scope of IFRS 2 Share-based Payment, leasing transactions that are within the scope of IAS 17 Leases, and measurements that have some similarities to fair value but are not fair value (e.g. net realisable value for the purposes of measuring inventories or value in use for impairment assessment purposes).

IFRS 13 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction in the principal (or most advantageous) market at the measurement date under current market conditions. Fair value under IFRS 13 is an exit price regardless of whether that price is directly observable or estimated using another valuation technique. Also, IFRS 13 includes extensive disclosure requirements.

Going concern

In accordance with their responsibilities, the directors have considered the appropriatness of the going concern basis, which has been used in the preparation of these financial statements.

During the course of 2014, we have begun to introduce ourselves to US and Chinese capital markets. Response to our progress has been strong as demonstrated by the participation of several US investors in the £10 million ($16.7m) raised in March 2014. We expect this exposure to the US investor base to increase significantly during the course of this year.

As a result of the extended delays involved in reaching the current operational stage, the Company has seen a substantial decrease in its stock price. It has nevertheless retained the support of key shareholders who currently account for more than 60% of the Company's shareholding.

The delays have meant that revenues have not grown as rapidly as expected. The Company is very encouraged by the progress made but, nevertheless, further funds will be required in the near term. The business plan approved by the Directors forecasts the need for this further funding and access to sufficient working capital to allow the operating businesses to reach full commercial scale. This is the principal risk to the business at the current time.

At the date of approval of these financial statements, the Group has yet to secure the additional funding requirements set out in the business plan and is, therefore, not fully-funded at the current time. However, given the success of the recent fund raising activities and the operational progress that has been achieved, the Directors are confident that this further funding will be achieved as required.

In preparing these financial statements, the Directors have assumed that sufficient further funding will be made available to the Group to enable it to execute its business plan and realise the forecast inflows from operations in Turkey and elsewhere.

In common with similar businesses at this stage of their development, and in light of the Group's dependence on further financing being made available to it from its shareholders or other providers of finance, the Directors consider the combination of these circumstances represent a material uncertainty that may cast significant doubt upon the Group's ability to continue as a going concern and, therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business.

Nevertheless, after making enquiries, and considering the uncertainties described above, the directors have a reasonable expectation that the Group will have access to adequate resources to continue in operational existence for the foreseeable future. For these reasons, they continue to adopt the going concern basis in preparing the financial statements.

The financial statements do not reflect any adjustments that would be required if the Group were unable to secure such financing to enable the Group to achieve profitability and positive cash flow, such that the going concern basis of preparation ceases to be appropriate.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR BLGDLCXDBGSL
Date   Source Headline
14th Apr 201610:00 amRNSUpdate and Resignation of Nominated Adviser
16th Mar 201612:37 pmRNSIssue of US$500,000 of Convertible Loan Notes
16th Mar 20167:00 amRNSIssue of US$500,000 of Convertible Loan Notes
25th Feb 20168:02 amRNSFunding Update and Statement re Suspension
25th Feb 20167:55 amRNSSuspension - Phorm Corporation Limited

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.